Cargando…

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis

BACKGROUND: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values, for the non-invasive diagnosis of steatosis in patients with or without chronic liver disease. Biomarkers and pan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poynard, Thierry, Ratziu, Vlad, Naveau, Sylvie, Thabut, Dominique, Charlotte, Frederic, Messous, Djamila, Capron, Dominique, Abella, Annie, Massard, Julien, Ngo, Yen, Munteanu, Mona, Mercadier, Anne, Manns, Michael, Albrecht, Janice
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1327680/ https://www.ncbi.nlm.nih.gov/pubmed/16375767 http://dx.doi.org/10.1186/1476-5926-4-10

Ejemplares similares

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2019)

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
por: Munteanu, M., et al.
Publicado: (2016)

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
por: Poynard, Thierry, et al.
Publicado: (2006)

Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data
por: Poynard, Thierry, et al.
Publicado: (2012)

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
por: Poynard, Thierry, et al.
Publicado: (2004)

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)
por: Munteanu, Mona, et al.
Publicado: (2004)

Assessment of Liver Fibrosis: Noninvasive Means
por: Poynard, Thierry, et al.
Publicado: (2008)

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
por: Poynard, Thierry, et al.
Publicado: (2019)

Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B
por: Poynard, Thierry, et al.
Publicado: (2011)

Meta-analyses of FibroTest diagnostic value in chronic liver disease
por: Poynard, Thierry, et al.
Publicado: (2007)

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
por: Bril, Fernando, et al.
Publicado: (2019)

Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers
por: Poynard, Thierry, et al.
Publicado: (2008)

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Ratziu, Vlad, et al.
Publicado: (2006)

An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Hirsch Index and Truth Survival in Clinical Research
por: Poynard, Thierry, et al.
Publicado: (2010)

Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison
por: Poynard, Thierry, et al.
Publicado: (2016)

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
por: Poynard, Thierry, et al.
Publicado: (2011)

Impact of steatosis and inflammation definitions on the performance of NASH tests
por: Poynard, Thierry, et al.
Publicado: (2018)

Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis
por: Rudler, Marika, et al.
Publicado: (2015)

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
por: Poynard, Thierry, et al.
Publicado: (2010)

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
por: Munteanu, Mona, et al.
Publicado: (2018)

Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19
por: Deckmyn, Olivier, et al.
Publicado: (2022)

Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia
por: Poynard, Thierry, et al.
Publicado: (2023)

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity
por: Poynard, Thierry, et al.
Publicado: (2015)

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease
por: Halfon, Philippe, et al.
Publicado: (2002)

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
por: Peta, Valentina, et al.
Publicado: (2017)

HEPATITIS VIRUS C INFECTION, ADIPOKINES AND HEPATIC STEATO–FIBROSIS
por: Ciurtin, C, et al.
Publicado: (2008)

Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series
por: Prodanovic, Hélène, et al.
Publicado: (2007)

Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant
por: Ratziu, Vlad, et al.
Publicado: (2006)

LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis
por: Poynard, Thierry, et al.
Publicado: (2018)

External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV
por: Poynard, Thierry, et al.
Publicado: (2021)

Lifestyle interventions for patients with non-alcoholic steato-hepatitis–Design, rationale and protocol of the study “target group-specific optimisation of lifestyle interventions for behavior change in non-alcoholic steato-hepatitis (OPTI-NASH)”
por: Krüger, Kathrin, et al.
Publicado: (2023)

A New SteatoScore in the Evaluation of Non-Alcoholic Liver Disease in Oncologic Patients
por: Cioni, Dania, et al.
Publicado: (2022)

Systematic review with meta‐analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B
por: Houot, M., et al.
Publicado: (2015)

Performance of serum apolipoprotein-A1 as a sentinel of Covid-19
por: Poynard, Thierry, et al.
Publicado: (2020)

Foetal programming by methyl donor deficiency produces steato-hepatitis in rats exposed to high fat diet
por: Bison, Anaïs, et al.
Publicado: (2016)

SteatoNet: The First Integrated Human Metabolic Model with Multi-layered Regulation to Investigate Liver-Associated Pathologies
por: Naik, Adviti, et al.
Publicado: (2014)

The Role of Growth Hormone and Insulin Growth Factor 1 in the Development of Non-Alcoholic Steato-Hepatitis: A Systematic Review
por: Cristin, Luca, et al.
Publicado: (2023)

Supplementation with crude rhubarb extract lessens liver inflammation and hepatic lipid accumulation in a model of acute alcohol-induced steato-hepatitis
por: Neyrinck, Audrey M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_shqhcovp4fljk6ucdgod82f2iq